RAC to finally relax gene therapy oversight

RAC to finally relax gene therapy oversight

The 40-year old Recombinant DNA Advisory Committee (RAC) is set to ease its oversight over gene therapy research, providing a welcome relief to US academics and companies working in the field. Everyone is happy, says Barry Byrne, director of the University of Florida Powell Gene Therapy Center and c...

Full description

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2014-09, Vol.32 (9), p.858-858
Main Author: Mullard, Asher
Format: Article
Language:eng
Subjects:
Advisory Committees
Committees
Deoxyribonucleic acid
DNA
DNA, Recombinant
Gene therapy
Genetic Therapy - legislation & jurisprudence
Humans
Management
National Institutes of Health (U.S.)
United States
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The 40-year old Recombinant DNA Advisory Committee (RAC) is set to ease its oversight over gene therapy research, providing a welcome relief to US academics and companies working in the field. Everyone is happy, says Barry Byrne, director of the University of Florida Powell Gene Therapy Center and chair of the Clinical Trials and Regulatory Affairs Committee at the American Society of Gene & Cell Therapy.
ISSN:1087-0156
1546-1696